In obese patients, which body weight (ideal, lean, or adjusted) should be used for propofol dosing?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Propofol Dosing in Obese Patients: Use Lean Body Weight or Adjusted Body Weight

For propofol dosing in obese patients, use lean body weight (LBW) or adjusted body weight (ABW) rather than total body weight to avoid overdosing, hypotension, and prolonged effects while maintaining adequate anesthesia depth. 1

Weight Scalar Recommendations

Primary Recommendation: Lean or Adjusted Body Weight

  • The Association of Anaesthetists guidelines explicitly recommend that lean or adjusted body weight be used as the scalars for calculating initial anaesthetic drug doses rather than total body weight in obese patients 1

  • Dosing to total body weight is rarely appropriate and increases the risk of relative overdose, particularly given that excess weight is predominantly fat tissue with relatively low blood flow 1

Calculating the Appropriate Weight Scalars

Lean Body Weight (LBW) can be calculated using the Janmahasatian formula 1:

  • Males: LBW (kg) = (9270 × TBW) / (6680 + 216 × BMI)
  • Females: LBW (kg) = (9270 × TBW) / (8780 + 244 × BMI)
  • Important caveat: LBW rarely exceeds 100 kg in men and 70 kg in women regardless of total body weight 1

Adjusted Body Weight (ABW) accounts for the increased lean body mass in obese individuals 1:

  • ABW (kg) = IBW (kg) + 0.4 × (TBW (kg) - IBW (kg))
  • This adds 40% of the excess weight to ideal body weight

Clinical Evidence Supporting LBW/ABW Dosing

Induction Dosing

  • The induction dose required to produce unconsciousness correlates well with lean body weight, as anesthesia occurs before redistribution from the central compartment 1

  • Research demonstrates that propofol dosing based on LBW provides adequate anesthetic effects in morbidly obese patients while avoiding complications 2

  • A study found that LBW-based dosing (2 mg/kg LBW) generated identical anesthetic effects in morbidly obese subjects compared with controls, while total body weight dosing led to decreased or equal plasma levels despite higher doses 2

  • The optimal propofol induction dose for morbidly obese patients (BMI ≥35) calculated on LBW is 2.310-3.567 mg/kg, providing satisfactory intubation depth with stable hemodynamics 3

Comparison Studies

  • A randomized trial comparing fat-free mass (FFM) versus ideal body weight (IBW) dosing found that FFM-based dosing (2 mg/kg) provided more adequate anesthesia than IBW dosing, with fewer patients requiring additional doses (2 vs 8 patients, P=0.032) 4

  • Research using adjusted body weight with the Schnider and Marsh target-controlled infusion models achieved the lowest predictive errors (MDPE <10%, MDAPE <25%) compared to total body weight 5

Critical Safety Considerations

Risk of Awareness

  • The NAP5 audit found a disproportionate number of obese patients who suffered accidental awareness under general anesthesia (AAGA) 1

  • Small doses of induction agent based on lean or adjusted body weight that are not quickly followed by maintenance anesthesia increase the risk of AAGA, as more rapid redistribution into larger fat mass causes patients to wake up more quickly than non-obese patients after a single bolus 1

  • When using target-controlled infusions with neuromuscular blocking drugs, depth of anesthesia monitoring is strongly recommended due to awareness risk 1

Hemodynamic Risks

  • Doses based on total body weight will last longer but are likely to result in significant hypotension 1

  • Morbidly obese patients show increased brain sensitivity to propofol, with EC50 values decreased by 37.9-38.6% compared to controls 2

Pharmacokinetic Alterations

  • Morbidly obese patients have significantly increased elimination clearance (223-243% of controls) and peripheral compartment volume (156-180% of controls) 2

  • Recent pharmacokinetic modeling demonstrates that total body weight is a covariate for clearance, lean body weight for central and rapid distribution volumes, and predicted normal weight for slow distribution volume 6

Practical Dosing Algorithm

For Induction (ASA I-II, <55 years)

  1. Calculate LBW or ABW using formulas above
  2. Administer propofol 2-2.5 mg/kg based on LBW/ABW 1
  3. Titrate approximately 40 mg every 10 seconds against clinical response 7
  4. Immediately establish maintenance anesthesia to prevent awareness 1

For Elderly, Debilitated, or ASA III-IV

  • Reduce dose to approximately 1-1.5 mg/kg LBW/ABW (approximately 20 mg every 10 seconds) 7
  • Avoid rapid bolus administration to minimize cardiorespiratory depression 7

Target-Controlled Infusion Limitations

  • The Marsh model becomes unreliable for patients >140-150 kg 1
  • The Schnider model has BMI limits of >35 kg/m² (female) and >42 kg/m² (male) 1
  • When using TCI in very obese patients, titrate to processed EEG values rather than relying solely on weight-based calculations 8

Common Pitfalls to Avoid

  • Never use total body weight for propofol dosing in obese patients - this leads to overdosing, hypotension, and prolonged recovery 1
  • Do not underdose to avoid hypotension - this increases awareness risk; instead use appropriate weight scalars and titrate carefully 1
  • Remember that LBW has a ceiling (100 kg men, 70 kg women) regardless of actual weight 1
  • Always follow induction doses immediately with maintenance anesthesia in obese patients due to rapid redistribution 1

References

6
Research

Pharmacokinetics of propofol in severely obese surgical patients.

Acta anaesthesiologica Scandinavica, 2024

Related Questions

In obese patients, how does propofol distribute into adipose tissue when administered via a Perfusor infusion, and what dosing adjustments are recommended?
A patient weighing 120 kg was started on a propofol infusion three days ago, and the current weight is now 123 kg. Should the propofol dose be adjusted to reflect the new weight?
In a morbidly obese patient with BMI approximately 42 kg/m², how accurate is the Eleveld target‑controlled infusion (TCI) model for propofol compared with the Marsh and Schnider models?
In a 125‑kg obese patient undergoing transforaminal lumbar interbody fusion (TLIF) spine surgery, can a target‑controlled infusion (TCI) of remifentanil (Minto model) be combined with sevoflurane, and should the remifentanil dose be calculated using ideal body weight rather than total body weight? What is the appropriate remifentanil infusion dosing?
What is the appropriate milliliter dose of a 1% propofol solution for induction per kilogram?
What are the differential diagnoses for a patient presenting with headache and a red eye?
What is the recommended dosage of pristinamycin for treating erysipelas in adults (including oral and intravenous regimens) and children, and how should the dose be adjusted in patients with markedly impaired renal function?
In obese patients, which body weight (ideal body weight or adjusted body weight) should be used for dosing dexmedetomidine?
What is the appropriate management for sinus tachycardia with ventricular trigeminy?
What are the differential diagnoses and recommended treatment for acute parotitis?
Is it common to prescribe metformin extended‑release (ER) twice daily instead of metformin immediate‑release (IR) to reduce gastrointestinal upset?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.